Dicerna Pharmaceuticals (DRNA) Stock Rating Lowered by BidaskClub

Dicerna Pharmaceuticals (NASDAQ:DRNA) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Tuesday, BidAskClub reports.

Several other analysts have also weighed in on the company. Chardan Capital raised Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Tuesday, January 22nd. ValuEngine raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 21st. Cowen assumed coverage on Dicerna Pharmaceuticals in a research note on Tuesday, February 26th. They set an “outperform” rating on the stock. B. Riley lifted their price target on Dicerna Pharmaceuticals from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th. Finally, SunTrust Banks lifted their price target on Dicerna Pharmaceuticals to $26.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $21.78.

NASDAQ:DRNA opened at $13.75 on Tuesday. The stock has a market capitalization of $993.18 million, a P/E ratio of -11.46 and a beta of 2.42. Dicerna Pharmaceuticals has a twelve month low of $9.31 and a twelve month high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The business had revenue of $1.54 million during the quarter, compared to analyst estimates of $8.38 million. Dicerna Pharmaceuticals had a negative net margin of 1,438.68% and a negative return on equity of 53.27%. Equities analysts predict that Dicerna Pharmaceuticals will post -0.99 EPS for the current fiscal year.

In other news, insider James B. Weissman sold 15,000 shares of Dicerna Pharmaceuticals stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $15.00, for a total transaction of $225,000.00. Following the sale, the insider now directly owns 39,480 shares of the company’s stock, valued at $592,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 19.85% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Bank of America Corp DE boosted its stake in shares of Dicerna Pharmaceuticals by 30.3% during the fourth quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 2,465 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Dicerna Pharmaceuticals by 38.7% in the fourth quarter. Legal & General Group Plc now owns 9,186 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 2,561 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Dicerna Pharmaceuticals by 512.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,459 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 2,894 shares during the period. State Board of Administration of Florida Retirement System lifted its stake in shares of Dicerna Pharmaceuticals by 19.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 18,234 shares of the biopharmaceutical company’s stock worth $195,000 after acquiring an additional 3,024 shares during the period. Finally, American International Group Inc. lifted its stake in shares of Dicerna Pharmaceuticals by 17.6% in the fourth quarter. American International Group Inc. now owns 35,409 shares of the biopharmaceutical company’s stock worth $379,000 after acquiring an additional 5,291 shares during the period. 85.29% of the stock is currently owned by hedge funds and other institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Article: What Does a Sell-Side Analyst Rating Mean?

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.